BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21761334)

  • 1. Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells.
    Katayama H; Sen S
    Horm Cancer; 2011 Apr; 2(2):117-24. PubMed ID: 21761334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells.
    Jiang S; Katayama H; Wang J; Li SA; Hong Y; Radvanyi L; Li JJ; Sen S
    Horm Cancer; 2010 Feb; 1(1):11-20. PubMed ID: 21761347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
    Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis.
    Sayeed A; Konduri SD; Liu W; Bansal S; Li F; Das GM
    Cancer Res; 2007 Aug; 67(16):7746-55. PubMed ID: 17699779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
    Lu W; Katzenellenbogen BS
    Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function.
    Liu W; Konduri SD; Bansal S; Nayak BK; Rajasekaran SA; Karuppayil SM; Rajasekaran AK; Das GM
    J Biol Chem; 2006 Apr; 281(15):9837-40. PubMed ID: 16469747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.
    Liu W; Ip MM; Podgorsak MB; Das GM
    Breast Cancer Res Treat; 2009 May; 115(1):43-50. PubMed ID: 18481172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression.
    Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J
    Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.
    D'Assoro AB; Liu T; Quatraro C; Amato A; Opyrchal M; Leontovich A; Ikeda Y; Ohmine S; Lingle W; Suman V; Ecsedy J; Iankov I; Di Leonardo A; Ayers-Inglers J; Degnim A; Billadeau D; McCubrey J; Ingle J; Salisbury JL; Galanis E
    Oncogene; 2014 Jan; 33(5):599-610. PubMed ID: 23334326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
    Swetzig WM; Wang J; Das GM
    Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
    Zheng XQ; Guo JP; Yang H; Kanai M; He LL; Li YY; Koomen JM; Minton S; Gao M; Ren XB; Coppola D; Cheng JQ
    Oncogene; 2014 Oct; 33(42):4985-96. PubMed ID: 24166501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.
    Bonofiglio D; Gabriele S; Aquila S; Catalano S; Gentile M; Middea E; Giordano F; Andò S
    Clin Cancer Res; 2005 Sep; 11(17):6139-47. PubMed ID: 16144913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.
    Akaogi K; Nakajima Y; Ito I; Kawasaki S; Oie SH; Murayama A; Kimura K; Yanagisawa J
    Oncogene; 2009 Aug; 28(32):2894-902. PubMed ID: 19503094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC3-ERα Selectively Regulates TNF-α-Induced Apoptotic Cell Death in MCF-7 Human Breast Cancer Cells via the p53 Signaling Pathway.
    Park SH; Kim H; Kwak S; Jeong JH; Lee J; Hwang JT; Choi HK; Choi KC
    Cells; 2020 May; 9(5):. PubMed ID: 32455774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines.
    Qiu J; Wang X; Guo X; Zhao C; Wu X; Zhang Y
    Oncol Rep; 2009 Oct; 22(4):935-41. PubMed ID: 19724876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells.
    Berger CE; Qian Y; Liu G; Chen H; Chen X
    J Biol Chem; 2012 Aug; 287(36):30117-27. PubMed ID: 22787161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora B kinase phosphorylates and instigates degradation of p53.
    Gully CP; Velazquez-Torres G; Shin JH; Fuentes-Mattei E; Wang E; Carlock C; Chen J; Rothenberg D; Adams HP; Choi HH; Guma S; Phan L; Chou PC; Su CH; Zhang F; Chen JS; Yang TY; Yeung SC; Lee MH
    Proc Natl Acad Sci U S A; 2012 Jun; 109(24):E1513-22. PubMed ID: 22611192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
    Phelps M; Darley M; Primrose JN; Blaydes JP
    Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
    Gao A; Sun T; Ma G; Cao J; Hu Q; Chen L; Wang Y; Wang Q; Sun J; Wu R; Wu Q; Zhou J; Liu L; Hu J; Dong JT; Zhu Z
    Nat Commun; 2018 Oct; 9(1):4180. PubMed ID: 30301939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.